Protagonist Therapeutics

Yahoo Finance • 12 hours ago

Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says

Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

We Did The Math IJR Can Go To $133

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 2 months ago

Protagonist therapeutics CEO Patel sells $570k in stock

Protagonist Therapeutics (NASDAQ:PTGX) President and CEO Dinesh V. Patel, Ph.D., sold 10,415 shares of common stock on July 25, 2025, at prices ranging from $54.75 to $54.82, for a total value of $570,533. The sale comes as the $3.48 billi... Full story

Yahoo Finance • 2 months ago

XSMO's Underlying Holdings Could Mean 15% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head... Full story

Yahoo Finance • 3 months ago

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story

Yahoo Finance • 4 months ago

Protagonist Therapeutics' SWOT analysis: promising pipeline drives stock outlook

Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company focused on developing novel therapies, has been making significant strides in its drug development pipeline. The company’s recent advancements in its lead candidates... Full story

Yahoo Finance • 4 months ago

For Patients With Rare Blood Cancer, New Drug Offers Relief

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening their blood and increasing the risk for cl... Full story

Yahoo Finance • 4 months ago

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop... Full story

Yahoo Finance • 8 months ago

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now.In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against the other cheap biotech stocks. Biotech Stocks F... Full story

Yahoo Finance • last year

Turnstone Biologics Appoints William Waddill to its Board of Directors

Turnstone Biologics Corp. SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure... Full story

Yahoo Finance • 2 years ago

Steven Cohen Adjusts Position in Protagonist Therapeutics Inc

Overview of Steven Cohen (Trades, Portfolio)'s Recent Stock Transaction Warning! GuruFocus has detected 5 Warning Signs with PTGX. Steven Cohen (Trades, Portfolio)'s firm, Point72 Asset Management, has recently made a notable adjustment... Full story

Yahoo Finance • 2 years ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's InvestigationalInjectable Hepcidin Mimetic Currentl... Full story

Yahoo Finance • 2 years ago

A Look At The Fair Value Of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Key Insights Protagonist Therapeutics' estimated fair value is US$27.16 based on 2 Stage Free Cash Flow to Equity With US$22.93 share price, Protagonist Therapeutics appears to be trading close to its estimated fair value Analyst price ta... Full story

Yahoo Finance • 2 years ago

Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment

Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235). JNJ-2113 is a macrocyclic pe... Full story

Yahoo Finance • 3 years ago

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomize... Full story

Yahoo Finance • 3 years ago

Why Protagonist Therapeutics Shares Are Trading Higher Today

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from its collaboration with Janssen Biotech Inc, a part of Johnson & Johnson (NYSE: JNJ), in the FRONTIER 1 Phase 2b trial of oral Interleukin-23 receptor (IL-23R) antag... Full story

Yahoo Finance • 3 years ago

Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting

NEWARK, Calif., Nov. 3, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that three abstracts related to the Company's rusfertide program have been accepted as poster presentati... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) (NASDAQ: PTGX).   Such investors are advised to contact Robert S... Full story